News about tests

New tests and other updates 2017

March 22, 2017 - Company News, Product News
New additions to our test menu: Entyvio (vedolizumab), anti-contactin 1 and anti-Neurofascin 155.

NEW tests no. 138/139 –  Therapeutic Drug Monitoring (TDM)

drug concentration and detection of anti-drug-antibodies of Entyvio (vedolizumab) treatment.

Vedolizumab (Entyvio) is a humanized monoclonal antibody against ?4?7 integrin and used for the treatment of inflammatory bowel diseases such as ulcerative colitis (UC) and Crohn´s disease (CD). Therapeutic cut-off (minimum serum concentration of Vedolizumab that gives a positive response to treatment) is still not known.

During treatment, some patients may develop antibodies to Vedolizumab (anti-drug antibodies or ADA). The assays are performed using ELISA and can only detect ADA if drug concentration in the serum is < 2 µg/mL. Detection limit for Vedolizumab anti-drug antibodies (ADA) determination is 35 ng/mL.

NEW test – anti-contactin 1 (no. 600)

(also included in panel no. 537 – CIDP)

The new test no. 600 (anti-contactin 1) will now be possible to order when there is a suspicion of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Contactin-1 (CNTN1) is a paranodal protein that is essential for the axo-glial junction and function of the node of Ranvier. IgG autoantibodies against CNTN1 can be detected in about 3-6% of patients with CIDP). This subgroup is characterized by aggressive symptom onset, axonal damage, sensory ataxia and poor response to treatment with intravenous immunoglobulin (IVIg). Some of these patients respond to treatment with steroids or plasmapheresis. It has been reported that treatment resistant cases have been responsive to treatment with rituximab (Querol L et al., 2015). Testing for autoantibodies against CNTN1 can thus be helpful in the choice of individualized treatment.

NEW test - anti-Neurofascin 155 (no. 601)

(also included in panel no. 537 – CIDP)

The new test no. 601 (anti-Neurofascin 155) will now be possible to order when there is a suspicion of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Neurofascin-155 (NF155) is a paranodal glial protein of importance for anchoring myelin to the axon and the function of the node of Ravier. IgG autoantibodies against NF155 have been identified in 5-10% of patients with CIDP. This subgroup is characterized by an aggressive course, young age at onset, sensory ataxia and disabling tremor. These patients often have a poor response to treatment with intravenous immunoglobulin (IVIg) or steroids but may respond to plasmapheresis or rituximab (Querol L et al., 2015). Testing for IgG-autoantibodies against NF155 can thus be valuable in the choice of individualized treatment.

Updates on the Neurology Request Form

We have removed the panel no. 564 Cunningham panel (Suspect PANS/CANS or PANDAS) from the Request Form Neurology and the panel can now be ordered on a separate Request Form called: Autoimmune Pediatric Neuropsychiatric Disorder. The panel contains 5 different tests: Serum induced activation of CaM Kinase II, and antibodies against Dopamine receptors (D1, D2), lyso-GM1 and beta-Tubulin. Request forms can be downloaded from the website or here.

« Back

Find test

Pick the way you would like to find a test
Test Quick Search
20 years experience